RESIDENTS AND FELLOWS
`
`Section Editor: Sumit "Sam" Garg, MD
`
`Topical Corticosteroid
`and NSAID Therapies
`for Ocular Inflammation
`
`A concise overview for clinical practice.
`
`BY GARRICK CHAK. MD; AMANDA E. KIELY. MD; AND PRATAP CHALLA, MD
`
`When beginning to prescribe anti-inflammatory medications, it is common to be confused with respect to the
`various preparations that are commercially available. What is the difiierence in potency between prednisolone,
`
`
`
`—
`
`loteprednol, and dfiluprednate? How do I choose which nonsteroidal drop to usefor my patient? In this second
`installmentfrom Dr. Garrick Chak and colleagues, they review the basics and intricacies ofophthalmic steroidal
`and nonsteroidalformulations Knowledge ofthe specifics detailed here will allow you to better tailor your medical manage-
`ment ofpatients As always, ifyou have any recommendationfor "Residents and Fellows,” please let me know.
`—Sumit ”Sam” Garg, MD, section editor
`
`opical corticosteroids and nonsteroidal anti-
`inflammatory drugs (NSA|Ds) are often used to
`treat ocular inflammation. An appreciation of
`the subtle differences may help physicians deter-
`mine which medication to prescribe as they strive to
`offer patient-centered care.
`
`via corticosteroids)? Corticosteroid therapies disrupt the
`inflammatory cascade by inhibiting the release of arachi-
`donic acid from cell membrane phospholipids thus pre-
`venting the fom1ation of prostaglandins (cyclooxygenase
`[COX] pathway) as well as Ieukotrienes and other inflam-
`matory mediators (lipoxygenase pathways).
`
`PEARLS FOR TOPICAL CORTICOSTEROI DS
`
`EFFICACY VERSUS POTENCY
`
`Topical ophthalmic corticosteroid agents can be clas-
`sified as ketone steroids (prednisolone, difluprednate,
`dexamethasone, fluorometholone, and rimexolone)
`or ester steroid (loteprednol) based on pharmacologic
`design. Loteprednol is formulated with an ester instead of
`a ketone group at the C-20 position.‘ Thought to be cata-
`ractogenic, the C-20 ketone group forms a covalent bond
`with lens proteins that are found only in steroid-induced
`cataracts‘ Although this is a widely accepted hypothesis
`for steroid-induced cataracts other mechanisms may exist.
`In clinical practice, corticosteroids are often grouped
`broadly by anti-inflammatory potency, defined as the
`binding affinity of the drug to the glucocorticoid receptor.
`As a brief review, the corticosteroid binds to a gIucocorti-
`coid receptor that is located in the cytosol. Once bound,
`the glucocorticoid receptor is activated and migrates into
`the nucleus where it modulates signaling pathways and
`protein expression (more than 5,000 genes are targeted
`
`The anti-inflammatory potency of a drug is a phar-
`macologically relative term—in some instances relative
`to hydrocortisone3 and in other instances relative to
`dexamethasone‘—and is not necessarily tantamount
`to its clinical efficacy topically. For instance, topical
`dexamethasone alcohol 0.1% is known to have a sixfold
`
`higher potency and double the half-life of topical pred-
`nisolone acetate 1% (Table 1). Even so, the latter attained
`a peak aqueous concentration that was more than 21 to
`36 times higher than the former and also persisted with
`a detectable drug aqueous concentration after 24 hours
`(whereas the former was undetectable) because of supe-
`rior penetration of the drugs Thus when selecting the
`appropriate corticosteroid for the patient, the eye care
`provider should note that the efficacy of a topical corti-
`costeroid comprises a combination of variables such as
`potency, vehicle, drug concentration, duration of action,
`and ocular penetration.
`
`NOVEMBER/DECEMBER 2014 CATARACT 8: REFRACTIVE SURGERY TODAY 15
`
`Page 1 of 5
`
`SENJU EXHIBIT 2155
`
`LUPIN v. SENJU
`
`IPR2015—01100
`
`

`
`RESIDENTS AND FELLOWS
`
`TABLE 1. TOPICAL CORTICOSTEROIDS IN THE UNITED STATES
`
`Topical Potency
`(Clinical Efficacy)
`
`Anti-inflammatory Potency
`(Relative to Hydrocortisone)
`
`Average IOP Rise, mm Hg
`
`Highest
`
`Difluprednate
`
`4
`
`25
`
`4
`
`25
`
`25
`
`25
`
`17.8
`
`10.0 + 1.7
`
`220 + 2.9
`
`1.7% with spike > 10 mm Hg
`(901 patients)
`
`2% with spike > 10 mm Hg
`(98 patients)
`
`40-50
`
`6.1 + 1.4
`
`Prednisolone
`acetate
`
`Dexamethasone
`acetate
`
`Prednisolone
`
`phosphate
`
`Loteprednol
`etabonate
`
`Rimexolone
`
`Dexamethasone
`
`phosphate
`Fluorometholone
`acetate
`
`Half-life of
`
`Drug, hrs
`
`2x as long as
`betamethasone
`
`18-36
`
`36-54
`
`18-36
`
`36-54
`
`Highest
`
`Higher
`
`Higher
`
`High
`
`Moderate
`
`Moderate
`
`Moderate
`
`Mild
`
`Mild
`
`Low
`
`Low
`
`—-
`alcohol--
`
`;—
`
`SOLUBILITY, PENETRATION, AND
`CONVENIENCE
`
`Within a class of corticosteroids, the acetate, the phos-
`phate, or the alcohol form—somewhere in between
`acetate and phosphate in the solubility spectrum—gives
`physicians an idea of the drug's propensity for corneal
`penetration and may change the relative anti-inflammatory
`efficacy of the drug, Aqueous humor samples have shown
`that prednisolone acetate achieves higher drug concen-
`trations than prednisolone sodium phosphate in the
`presence of an intact corneal epithelium.‘ The acetate
`form is more Iipophilic and available as a suspension,
`which leads to longer contact time and better penetra-
`tion. The phosphate form is more hydrophilic, however,
`and is available as a solution. Topical prednisolone sodi-
`um phosphate 1% is less effective than topical predniso-
`lone acetate 1% due to bioavailability and penetration
`(lower ability to achieve high aqueous humor concentra-
`tion of the drug through an intact corneal epithelium).7
`Generally, a suspension (for instance, prednisolone
`acetate) must be shaken vigorously for the medication to
`be homogenous upon application} whereas a solution
`(eg. prednisolone sodium phosphate), an emulsion
`
`(eg. difluprednate), or a gel (eg. loteprednol etabonate)
`removes this responsibility from those who find shaking
`agitating Even among prednisolone acetate suspensions,
`a generic version has been shown to have poorer dose
`uniformity and may require more shaking in order to
`achieve the same dose uniformity as a brand-name ver-
`sion.° Besides the convenience of not requiring shaking,
`difluprednate 0.05% does not contain benzalkonium
`chloride (BAK); instead it uses sorbic acid as a preserva-
`tive. Alternative topical corticosteroids without BAK
`include preservative-free dexamethasone 0.1%, preserva-
`tive-free loteprednol 0.5%, and compounded preserva-
`tive-free methylprednisolone 1%. Table 1 provides a quick
`reference list of topical corticosteroids that are frequently
`prescribed in the United States.“““
`
`RISK AND REWARDS, IOP ELEVATION
`
`With corticosteroid therapy, higher anti-inflammatory
`rewards do not come without the potential for higher
`risk, such as IOP elevation, cataractogenesis, epithelial
`breakdown into a geographic ulcer if administered in the
`presence of a herpetic dendritic ulcer, and fungal infec-
`tion with long—term corticosteroid use. Generally, the risk
`
`15 cArArBagg<g2R9<fr5E SURGERY TODAY NOVEMBER/DECEMBER 2014
`
`

`
`RESIDENTS AND FELLOWS
`
`TABLE 2. NSAIDS IN THE UNITED STATES
`
`Bromfenac
`
`Xi brom 0.09%
`
`Fon'nerly Ista Pharmaceuticals; now
`generic
`
`Bromday 0.09%
`
`Diclofenac
`
`Voltaren 0.1%
`
`Ophtha CD
`Voltaren 0.1%
`
`Ophtha
`
`Dicloftil 0.1%
`
`Bausch + Lomb
`Bausch + Lomb
`Alcon
`
`Alcon
`
`Fammigea
`(not available in the United States)
`
`Flurbiprofen
`
`Ocufen 0.03%
`
`Ketorolac
`
`Acular 0.5%
`
`Acular LS 0.4%
`
`Acuvail 0.45%
`
`Allergan
`
`Allergan
`
`Allergan
`
`Allergan
`
`Nepafanafi
`
`llevro
`
`Alcon
`
`Dosing
`
`COX-2 ICSO,
`pm
`
`Preservative
`
`0.023
`
`Benzalkoniwn
`
`Dai
`
`Dai
`
`q.i.d
`
`0.085
`
`chloride (BAK) 0.(X)5%
`BAK 0.005%
`
`BAK 0.005%
`
`BAK 0.005%
`
`M Thimerosa|0.005%
`3 BAK0-01%
`- BAKO-006%
`M‘ Preservative free
`BAKo.0o5%
`- BAK0.00S%
`
`for a steroid-related IOP spike is correlated to the poten-
`cy of the topical steroid; other influencing factors include
`the duration and frequency of the drug's administration
`as well as the susceptibility of the individual.
`About one-third of the general population are potential
`moderate steroid responders (IOP increase of 6-1 5 mm
`Hg). About 5% to 6% of the general population, in addition
`to the 33% mentioned previously, are severe responders
`(IOP increase > 15 mm Hg with many havinga marked
`IOP increase of > 31 mm Hg after 4-6 weeks of topical ste-
`roid use).‘5"‘ Despite proper tapering of topical corticoste-
`roid therapy, IOP may not necessarily decrease in steroid-
`responsive patients who are at increased risk of developing
`open-angle glaucoma. Also, topical corticosteroids may
`yield a crossover effect with IOP elevation in the fellow eye
`from systemic absorption.” The provider should be aware
`that corticosteroid use may lead to a dose-dependent IOP
`spike that occurs more frequently, more severely, and more
`rapidly in children than in adults“
`Due to the potential IOP elevation with the stronger
`corticosteroids, "softer" corticosteroids have been stra-
`
`tegically designed to reduce the risk of IOP elevation.
`Loteprednol and rimexolone are rapidly hydrolyzed into
`their respective inactive metabolite, and f|uorometho-
`|one—despite a surprisingly high pharmacologic poten-
`cy—is considered a soft steroid because of its limited
`corneal penetration.‘ Placebo-controlled trials have been
`
`conducted, but there has not been a randomized head-
`
`to-head comparison of the softer steroids
`By knowing the profile of each corticosteroid, an oph-
`thalmic provider can select the most appropriate anti-
`inflammatory medication for the patient.
`
`NSAID PEARLS
`
`NSA|Ds produce a variety of ocular effects The grow-
`ing body of scientific evidence suggests they may be
`beneficial in diabetic retinopathy, diabetic macular
`edema, age-related macular degeneration, and even ocu-
`lar tumors. The longest-standing and most widespread
`uses of NSA|Ds, however, are for reducing postoperative
`inflammation and preventing and treating cystoid macu-
`lar edema (CME) associated with intraocular surgery.
`This article focuses on those applications.
`NSA|Ds reduce inflammation by inhibiting COX
`enzymes (COX-1 and COX-2), thereby limiting the produc-
`tion of prostaglandins via the arachidonic acid cascade.
`Prostaglandins mediate multiple inflammatory changes
`increasing vasodilation and vascular permeabi|ity.‘°'2° In the
`eye, the drugs also disrupt the blood-aqueous barrier, lead-
`ing not only to iritis but also increasing the risk ofCME as
`inflammatory mediators leak into the eye. Topical NSA|Ds
`have been shown to be more effective than corticosteroids
`
`in re-establishing the blood-aqueous barrier and can thus
`play a critical role in the management of postoperative
`
`1s cArArBag323R9<fr§E SURGERY TODAY NOVEMBER/DECEMBER 2014
`
`

`
`RESIDENTS AND FELLOWS
`
`and other ophthalmic inflammation.” When choosing an
`NSAID, several factors are worth considering
`
`dosed three times daily after cataract surgery, based
`on measures of anterior chamber inflammation, BCVA,
`
`E F F I CACY
`
`As a rule, the inhibition of COX-2—inducible in inflam-
`
`matory conditions—determines the clinical efficacy of
`an ophthalmic NSAID (Table 2).’“3 Interestingly, how-
`ever, evidence does not support a direct correlation
`between in vitro potency, measured by the ICSO (the
`concentration required to reduce enzyme activity to
`half), and either bioavailability or medication effective-
`ness.“ Flach et al compared the anti-inflammatory effects
`of diclofenac (ICSO = 0.085 um) and ketorolac (ICSO =
`0.12 pm) in a double-masked study of 120 postoperative
`patients using both a laser cell and flare meter and clinical
`observation. The investigators found the two treatments
`to be equivalent.” Bromfenac has the lowest ICSO of the
`group (0.023 um), indicating greatest potency. A 2007
`study, however, compared the in vivo concentration and
`in vitro PGE2 inhibition of amfenac, its prodrug nepaf-
`enac (nepafanac is converted to bioactive amfenac pri-
`marily by ocular tissue hydrolasesz‘), ketorolac, and brom-
`fenac. Nepafenac proved to be most bioavailable with
`the shortest time to peak concentration and the highest
`peak aqueous humor concentration. Amfenac was more
`potent at COX-2 inhibition than either bromfenac or
`ketorolac (the most potent COX-1 inhibitor)"
`On the other hand, another study conducted that
`same year suggested ketorolac was as effective as nepaf-
`enac clinically (assessed using BCVA, anterior chamber
`inflammation on examination, and pain control) and
`perhaps better tolerated, with greater reported satisfac-
`tion and compliance among patients.’“9
`Although flurbiprofen reduces intraoperative miosis
`and inflammation after cataract surgery, the weight of
`the scientific evidence suggests it is less effective than
`other available NSA|Ds.3°
`
`DOSING SCHEDULE
`
`While maximizing drug effect may be necessary in
`some patients (eg, those with persistent macular edema),
`in many routine cases, it is just as important that ease
`of drop use facilitates patients’ adherence to therapy.
`Several studies have examined reduced dosing schedules
`for bromfenac, ketorolac, and nepafenac. Among dosing
`schedules for nepafenac, dosing three times a day resulted
`in better pain control on day 1 after cataract surgery. By
`postoperative day 3, patients using nepafenac only once
`daily were equally comfortable, however, and by day 14,
`there was no measureable difference in inflammation.”
`
`A more recent small study suggested that bromfenac
`administered just once daily was equivalent to nepafenac
`
`macular volume/retinal thickness, and IOP.” Twice-daily
`dosing of ketorolac has been evaluated versus placebo
`but not head-to-head with other agents
`
`SIDE EFFECTS
`
`In the 19905, reports of corneal melting associated with
`topical NSAID use caused significant concern in the oph-
`thalmology community. Most cases were associated with
`a now-discontinued diclofenac product (DSOS) and felt
`to be related to the vitamin E-based solubilizer tocopher-
`solan it contained.”*33 However, a few cases of corneal
`melt have since been associated with other formulations
`
`of ophthalmic diclofenac. One proposed mechanism is
`depletion of the neuropeptide substance P within the cor-
`neal epithelium, which is associated with delayed wound
`healing and a risk of neurotrophic keratopathy.“ It is also
`speculated that diclofenac increases the production of
`lipoxygenase-derived LTB4, a polymorphonuclear chemo-
`tactic, leading to corneal inflammation and melting”
`
`CO N C L U S I O N
`
`In general, the ophthalmic practitioner should consider
`the patient's profile when prescribing topical corticosteroids
`or NSA|Ds With corticosteroids, matching the penetration
`and potency of the drug with consideration of clinical con-
`text, contraindications, monitoring of the potential devel-
`opment of open-angle glaucoma, and the patient‘s physical
`limitations guides selection of the topical corticosteroid
`that is most appropriate for the patient. Before prescribing
`an NSAID, it behooves practitioners to determine whether
`a patient is predisposed to delayed wound healing (as in
`diabetes, rheumatoid arthritis, or other autoimmune inflam-
`matory conditions) or has likely corneal denervation (as in
`severe ocular surface disease, a history of herpetic keratitis,
`or after multiple complex ocular surgeries). Certainly, as
`with topical steroids, patients should not follow a pro-
`longed, unsupervised course of topical NSA|Ds. I
`
`Section Editor Sumit "Sam" Garg, MD, is the medical direc-
`tor, vice chair ofclinical ophthalmology, and an assistant
`professor ofophthalmology at the Gavin Herbert Eye Institute
`at the University ofCalifornia, Irvine, School ofMedicine. He
`also serves on the ASCRS Young Physicians and Residents
`Clinical Committee and is involved in residents’andfellows’
`education. Dr. Carg may be reached at garg5@uci.edu.
`Garrick Chak, MD, and Amanda
`
`E. Kiely, MD, are glaucomafellows
`at the Duke Eye Center in Durham,
`North Carolina. They both acknowl-
`edged no financial interest in the
`
`
`
`20 CATA
`
`rBageRr4Ro<fTS
`
`E SURGERY TODAY NOVEMBER/DECEMBER 2014
`
`

`
`products or companies mentioned herein. Dr. Chak may
`be reached at garrick.chak@dm.duke.edu, and Dr. Kiely
`may be reached at amanda.kiely@dm.duke.edu.
`Pratap Challa, MD, is the director of the
`ophthalmology residency program and an
`1
`associate professor of ophthalmology at the
`‘
`Duke Eye Center in Durham, North Carolina ‘‘
`
`
`
`r
`
`He acknowledged nofinancial interest in the
`products or companies mentioned herein. Dr. Challa may
`be reached at pratap.challa@dmduke.edu
`1. Comstock TL Decory HH. Advantes in cortitzosteruid therapy forocrlar irfammatiort lotqaredrol etabonate lntl
`lnflorrr. 2012;20127l19623.
`2 Gdowslo'JA. Glrroxmicoidsand their actions in cells ileum. 2082916]521-523.
`3. Meiialc Steroid equiialence talculator. httpi/www.medt3ltcotn/steroid.|'arnl AccessedOttober 1S, 2014
`4 Kelly HW. (ornparison ofinhakd corticosteroids. AnnPlrorrrracother. 19%;32220-232.
`5. Awan MA, Agarwal PK, Watson DQ etal. Penetrationoftopital and subconjunairal tmicosteroids into human
`aqueous humorand ‘nstherapurtit sigrifitarrce Br}Qrlrrhoinol K119932713-713.
`6 Krrplemran A, lfibowitzHM. Biological equivalence ofoplrthalnicprednisolom acetate suspensions Am]armhol-
`mol. 1976;82:109-113.
`7. MtfiheeCNJ, Noble MJ,Watson IX, et al. Paretratiotr oftopiallyapplied prednisolone sodium phosphate into human
`aqienus humour.Eye. 1989,3353-467.
`8 Fistrlh l1G,Jmsen M, Van D/dtG Generic prednisolonesuspension 9.rbst‘trrtion. Ardr Oplrmdnrol. 1998,-116(5):7fl3.
`9. StringerW, Bryant R Dose uniformityoftopitalcorticosteroid preparatiorrs: diluprednateophthalmic arrulsion005%
`versus branded and generic prednisolorre acetate ophthaknicsuspensiotr 196. OnOplrrirairrol. Z010,«4:1119-1124.
`10 SdrimmerBP, PatloerKL. Adrenocorticotmpit hormone; adrenotnttical steroids andtheirsyntheticanalogs; inhibitors
`ofthe synthesis andactions ofadrenomrtital hormones In: llardman JG, lirnhird LE,Gilrnan AG, eds. 6oodlnon&
`Gilnarls ilrePhorrnamIogtolBasr's rfllierqrarrics. 10th ed llew York, NY: Mrfiraw-Hill; 2111121649-1677.
`11. Rice DJ, Colby KA Sobrin L, llapuano Cl. 0/irtIrurrrroIogi:Drrrg6ur'de. 2nd ed. New York NY: SpringerSdence &
`Business Media; 201070
`12. Kersey P, Broadway [X Corticosteroid-hducesdghutnna: a rerrewofthe literature Eye. ZI620407-416
`13. Pleyer U, Utscl PG, Rama P. lntraourbrpressureefleusofcommontopical steroids forpostataract inflammation:
`arethey all the same? Qrllhahrd lira. 2013255-72
`14. Tajilta T, Walti M, lsuzuki M, etal. Pharmacoltineticfeatures ofdilluprodnate ophthalmicemulsion in rabbits as
`determined by grrcoconicuid receptot—binding bioassay. l0a1lPhormaod iher. 2EI11;27(1):29-34.
`15. Jorrs III R RheeDJ. Cortitosteroid~irrduoed ourlarhypertension andglaucoma: a briefresitw and update ofthe
`literature anqrrnqrlrtlrraind. 2ll16;17:16?-167.
`16 Cohen A. Steroidindrcedglauaxna. In: Rumelt S, at t7mro1rro1Bastorrd(]rrtdCortepIs.lttpl/rmmintedropar.
`(om/booldglaucoma-basic-and-c|irrical~mr1trptslsteroid—indut1d—glauconra. Amessed October 13,2014.
`17. Palmherg PF, Mande|lA, WrlensltyJ1, et al. The reproducfivityofthe irrtraocrrlat pressure nsponse to dexametha-
`sone Am}Qrlrhalrnd. 1975,-KX844-856
`18 Lam DSC Fan DSP, lhJSK, etal. Ocularhypertensive and anti—lnfammatory responsesto diflerurtdomesoftopital
`dexamethasotre in drildrenz a randomized trial. Girrbpermerrtoplrdrdrnol 2lX)S;33(3):Z52-258
`19. Ophthrlmic NSA|Ds Review (11181. ProridetSynergies, LLC httpsJ/lmrr.medicaid.rrr.govlDt7rvrrloads/providrr/
`NVh:_lXR_2lIm326_0phtlialmic_NSA|Dspdf. Accessed Septurrber24, ZIJ14.
`20 Rmerr 5. Preoperativeand postoperatite medications used forcataract surgery. (rrrrqiiroplrthdrrol. 1999,1099-35.
`Z1. Jampol LM, lainS, Pudziz B, Weinreb RN. llonsteroidal anti-irdlamrnatory dnrgsand tataraa surgery.;1/dr
`0;1rtlralrnol1994;112(7):891-894
`R Gallemore RP. llSA|Dsintreatmentofretinal disorders I1m'ewcf0;frtIrdrnoIogy.2lI5;6(45):81.
`B. Kim SJ, FladrAJ, larnpol LM. Nonsreroida|anti—inIammrtotydrrrgs in ophlha|mo|ogy.S1rv0mthotrroI.
`Z01l.‘r,SSl7):1lJ&133.
`24. WarnerTD, Vojnovic l, Bishop-Baiey D, Mitdrll JA. Inlluencetrfplasrna proieinson the potencisofinhibitors of
`tyt|ooxygenase—1 and -2. FASEBJ. 2fl)6;Z0(3l542—544.
`E. Flach Al, Dolan Bl, Donahue ME, eta|.(omparativeel‘1e(tsof|retoro|ac0 9%ordidofmac019li ophtlalmic solutions
`on inflammation aha cataract surgery. Qrlrthalrnobgy. 19J8;1OS(9):177S-1779.
`26 GaynesBl,01yekwrrlrrje A. Topital ophthalmic NSA|Ds a disorssiotrwith focus on nepafenac ophthalmicsuspension.
`Gin Oplrdratnol. 2&3; 21212355-368
`D. WaltersT, Raizman M, ErnestP, et al. In sivophamntnkmits and in vitrophamratodynamics ofnepalenac,
`amfenac, loetorolac, and bromfenacl (oraractlHaa5urg. ZOEI7,-33[9):1S3§¥1545.
`23 Maxwell WA, Rdser |-ll,Stewar1ll-l, etal. Nqrafenacdosing frequenty for ocular pain and inflammation amtiated
`with cataractsurgery. l0arlPhnrrrramI ilrer. 2lIl8;24(6):593-S99.
`D. Duong llV, Westfield KC, Chalkley TH. Ketorolat tromcihamine [S 0.4%versus nepafenat 01% in patients having
`tataraa surgery. Prospective randomized double-rnasloed dinital trial. .l0xrrrocrlb9mSurg. 2D0'l;33(11):19E-1929.
`30 Elaydts JEJ, Kelley E’, Walt L, etal. Flurhiptoferr 00396 forthe control ofinflammation fol|orM'ng cataract extraction
`by plracoerrrulsifitatiotrlfamrotrltimtsrirg. 1993,1914]:-181-487.
`31. Cable M. Comparison ofbromfenac009% CID to nqaafanac01% TID ahurataractsurgay pilotevaluation ofsisual
`acuity, maarlar vdume, and rainal thidtnessata sirgleslte drroylrtlralnol 2012,6997-11114.
`32 Gaynes Bl, liscella ll Topical notrsteroidal arrriinthmmatotydrugs forophthalrric use.DrugSdey. 21X)2,-2’5:2334»
`B50.
`33. Corrgdon llG, Schein 0D, van Kulajta P, et al. Corneal corrplicatiotrsassochtedwith topitalophthalnic use of
`nonsteroidal antiinllammatotydrugs.lCartmallefro<r5rrry. 2(I)1;27(41:622631.
`34. Yamada M, Ogata M, llawai M, et al. Topital cfidofenacsodium deaeases substanceP content i1 tears.Ardr
`Ofirtlrorlnol 2l102;120S1-54.
`
`Page 5 of 5